All In MedTech

Device Trial Radar · NCT04629521

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

An Observational Multicenter Clinical Study to Provide Additional Long-Term Follow-up Beyond 60 Months for Subjects Implanted With a CyPass Micro-Stent in the COMPASS Trial

Last checked: Nov 20, 2026Latest source record: Apr 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

54

Actual

Start

Dec 21, 2020

Primary completion

Apr 5, 2023

Study completion Apr 5, 2023

Sponsor

Lead sponsor
Alcon ResearchNot on our public-company list
Sponsor type
Industry
First posted
Nov 16, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess long-term (10 years post-CyPass implantation) status of the corneal endothelium in subjects who were implanted with the CyPass Micro-Stent in the COMPASS trial.

Conditions

  • Primary Open Angle Glaucoma
  • Cataract

Interventions

  • CyPass Micro-StentDevice

    The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.

  • Cataract SurgeryProcedure

    Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Eyes With Sight-threatening Adverse Events (AEs)Time frame: Month 96 (Year 8) to Month 120 (Year 10) postoperative
  2. Percentage of Eyes With Ocular Adverse EventsTime frame: Month 96 (Year 8) to Month 120 (Year 10) postoperative
  3. Central Endothelial Cell Density (ECD) Reported by Mean and Standard DeviationTime frame: Month 96 (Year 8), Month 108 (Year 9), Month 120 (Year 10) postoperative

60 more outcomes with a free account

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Eye Physicians and Surgeons of Arizona

    Glendale, Arizona

  • Coastal Vision Medical Group

    Orange, California

  • Eye Center of Northern Colorado, PC

    Fort Collins, Colorado

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.